What is C-Path?



Critical Path Institute: Accelerating the path to a healthier world 




Critical Path Institute, or C-Path, is a nonprofit organization that brings together biopharmaceutical firms,
universities, patient groups, and regulatory agencies from around the world to improve public health.
Together, these stakeholders work to identify or create tools that can accelerate the drug development and regulatory review process.


C-Path manages collaborative teams, or consortia, in which diverse stakeholders combine intellectual and
financial resources to create tools that facilitate the development of safe and effective medical products.

C-Path's consortia focus on specific patient populations, therapeutic areas, or drug development challenges. These include Alzheimer's disease, multiple sclerosis, Parkinson's diseases, tuberculosis, neonatal therapies, and drug safety testing, among others.

C-Path actively builds consensus across all these stakeholders. We share ideas, we share data, and we share risks and costs to
move the science forward.



Each team's goal is to create tools that will accelerate the drug development process and shorten the time it takes for a therapy to reach patients. C-Path focuses on regulatory qualification of biomarkers and clinical outcome assessment tools, regulatory approval of predictive modeling and simulation tools, and increased data sharing to accomplish the goal of shortening the
drug development timeline.



We are a trusted, neutral third party with the purpose of forming consortia to advance regulatory science and
increase the speed of drug development.